|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the LLY 10-K filed Feb 22, 2010. Revenue
Recognition and Sales Return, Rebate, and Discount
Accruals
We recognize revenue from sales of products at the time title of
goods passes to the buyer and the buyer assumes the risks and
rewards of ownership. For more than 85 percent of our
sales, this is at the time products are shipped to the customer,
typically a wholesale distributor or a major retail chain. The
remaining sales, which are outside the U.S., are recorded at the
point of delivery. Provisions for returns, rebates, and
discounts are established in the same period the related sales
are recorded.
We regularly review the supply levels of our significant
products sold to major wholesalers in the U.S. and in major
markets outside the U.S., primarily by reviewing periodic
inventory reports supplied by our major wholesalers and
available prescription volume information for our products, or
alternative approaches. We attempt to maintain wholesaler
inventory levels at an average of approximately one month or
less on a consistent basis across our product portfolio. Causes
of unusual wholesaler buying patterns include actual or
anticipated product supply issues, weather patterns, anticipated
changes in the transportation network, redundant holiday
stocking, and changes in wholesaler business operations. In the
U.S., the current structure of our arrangements does not provide
an incentive for speculative wholesaler buying and provides us
with data on inventory levels at our wholesalers. When we
believe wholesaler purchasing patterns have caused an unusual
increase or decrease in the sales of a major product compared
with underlying demand, we disclose this in our product sales
discussion if we believe the amount is material to the product
sales trend; however, we are not always able to accurately
quantify the amount of stocking or destocking. Wholesaler
stocking and destocking activity historically has not caused any
material changes in the rate of actual product returns.
We establish sales return accruals for anticipated product
returns. We record the return amounts as a deduction to arrive
at our net product sales. Once the product is returned, it is
destroyed. Consistent with Revenue Recognition accounting
guidance, we estimate a reserve when the sales occur for future
product returns related to those sales. This estimate is
primarily based on historical return rates as well as
specifically identified anticipated returns due to known
business conditions and product expiry dates. Actual product
returns have been less than one percent of our net sales over
the past three years and have not fluctuated significantly as a
percent of sales.
We establish sales rebate and discount accruals in the same
period as the related sales. The rebate and discount amounts are
recorded as a deduction to arrive at our net product sales.
Sales rebates and discounts that require the use of judgment in
the establishment of the accrual include Medicaid, managed care,
Medicare, chargebacks, long-term-care, hospital, patient
assistance programs, and various other government programs. We
base these accruals primarily upon our historical rebate and
discount payments made to our customer segment groups and the
provisions of current rebate and discount contracts.
The largest of our sales rebate and discount amounts are rebates
associated with sales covered by Medicaid. In determining the
appropriate accrual amount, we consider our historical Medicaid
rebate payments by product as a percentage of our historical
sales as well as any significant changes in sales trends, an
evaluation of the current Medicaid rebate laws and
interpretations, the percentage of our products that are sold to
Medicaid recipients, and our product pricing and current rebate
and discount contracts. Although we accrue a liability for
Medicaid rebates at the time we record the sale (when the
product is shipped), the Medicaid rebate related to that sale is
typically paid up to six months later. Because of this time lag,
in any particular period our rebate adjustments may incorporate
revisions of accruals for several periods.
Most of our rebates outside the U.S. are contractual or
legislatively mandated and are estimated and recognized in the
same period as the related sales. In some large European
countries, government rebates are based on the anticipated
pharmaceutical budget deficit in the country. A best estimate of
these
28
rebates, updated as governmental authorities revise budgeted
deficits, is recognized in the same period as the related sale.
If our estimates are not reflective of the actual pharmaceutical
budget deficit, we adjust our rebate reserves.
We believe that our accruals for sales returns, rebates, and
discounts are reasonable and appropriate based on current facts
and circumstances. U.S. sales returns, federally mandated
Medicaid rebate and state pharmaceutical assistance programs
(Medicaid) and Medicare rebates reduced sales by
$1.20 billion, $1.03 billion, and $738.8 million
in 2009, 2008, and 2007, respectively. A 5 percent change
in the sales return, Medicaid, and Medicare rebate amounts we
recognized in 2009 would lead to an approximate $60 million
effect on our income before income taxes. As of
December 31, 2009, our sales returns, Medicaid, and
Medicare rebate liability was $692.3 million.
Our global rebate and discount liabilities are included in sales
rebates and discounts on our consolidated balance sheet. Our
global sales return liability is included in other current
liabilities and other noncurrent liabilities on our consolidated
balance sheet. Approximately 84 percent and 80 percent
of our global sales return, rebate, and discount liability
resulted from sales of our products in the U.S. as of
December 31, 2009 and 2008, respectively. The following
represents a roll-forward of our most significant
U.S. returns, rebate, and discount liability balances,
including Medicaid (in millions):
These excerpts taken from the LLY 10-K filed Feb 27, 2009. Revenue
Recognition and Sales Return, Rebate, and Discount
Accruals
We recognize revenue from sales of products at the time title of
goods passes to the buyer and the buyer assumes the risks and
rewards of ownership. For more than 90 percent of our
sales, this is at the time products are shipped to the customer,
typically a wholesale distributor or a major retail chain. The
remaining sales, which are outside the U.S., are recorded at the
point of delivery. Provisions for returns, rebates, and
discounts are established in the same period the related sales
are recorded.
We regularly review the supply levels of our significant
products sold to major wholesalers in the U.S. and in major
markets outside the U.S., primarily by reviewing periodic
inventory reports supplied by our major wholesalers and
available prescription volume information for our products, or
alternative approaches. We attempt to maintain wholesaler
inventory levels at an average of approximately one month or
less on a consistent basis across our product portfolio. Causes
of unusual wholesaler buying patterns include actual or
anticipated product supply issues, weather patterns, anticipated
changes in the transportation network, redundant holiday
stocking, and changes in wholesaler business operations. In the
U.S., the current structure of our arrangements eliminates the
incentive for speculative wholesaler buying and provides us
improved data on inventory levels at our wholesalers. When we
believe wholesaler purchasing patterns have caused an unusual
increase or decrease in the sales of a major product compared
with underlying demand, we disclose this in our product sales
discussion if we believe the amount is material to the product
sales trend; however, we are not always able to accurately
quantify the amount of stocking or destocking. Wholesaler
stocking and destocking activity historically has not caused any
material changes in the rate of actual product returns.
We establish sales return accruals for anticipated product
returns. We record the return amounts as a deduction to arrive
at our net sales. Once the product is returned, it is destroyed.
Consistent with SFAS 48, Revenue Recognition When Right of
Return Exists, we estimate a reserve when the sales occur for
future product returns related to those sales. This estimate is
primarily based on historical return rates as well as
specifically identified anticipated returns due to known
business conditions and product expiry dates. Actual product
returns have been approximately one percent of our net sales
over the past three years and have not fluctuated significantly
as a percent of sales.
We establish sales rebate and discount accruals in the same
period as the related sales. The rebate and discount amounts are
recorded as a deduction to arrive at our net sales. Sales
rebates and discounts that require the use of judgment in the
establishment of the accrual include Medicaid, managed care,
Medicare, chargebacks, long-term-care, hospital, patient
assistance programs, and various other government programs. We
base these accruals primarily upon our historical rebate and
discount payments made to our customer segment groups and the
provisions of current rebate and discount contracts.
The largest of our sales rebate and discount amounts are rebates
associated with sales covered by Medicaid. In determining the
appropriate accrual amount, we consider our historical Medicaid
rebate payments by product as a percentage of our historical
sales as well as any significant changes in sales trends, an
evaluation of the current Medicaid rebate laws and
interpretations, the percentage of our products that are sold to
Medicaid recipients, and our product pricing and current rebate
and discount contracts. Although we accrue a liability for
Medicaid rebates at the time we record the sale (when the
product is shipped), the Medicaid rebate related
to that sale is typically paid up to six months later. Because
of this time lag, in any particular period our rebate
adjustments may incorporate revisions of accruals for several
periods.
Most of our rebates outside the U.S. are contractual or
legislatively mandated and are estimated and recognized in the
same period as the related sales. In some large European
countries, government rebates are based on the anticipated
pharmaceutical budget deficit in the country. A best estimate of
these rebates, updated as governmental authorities revise
budgeted deficits, is recognized in the same period as the
related sale. If our estimates are not reflective of the actual
pharmaceutical budget deficit, we adjust our rebate reserves.
We believe that our accruals for sales returns, rebates, and
discounts are reasonable and appropriate based on current facts
and circumstances. Sales returns, federally mandated Medicaid
rebate and state pharmaceutical assistance programs (Medicaid)
and Medicare rebates reduced sales by $1.03 billion,
$738.8 million, and $704.8 million in 2008, 2007, and
2006, respectively. A 5 percent change in the sales return,
Medicaid, and Medicare rebate amounts we recognized in 2008
would lead to an approximate $52 million effect on our
income before income taxes. As of December 31, 2008, our
sales returns, Medicaid, and Medicare rebate liability was
$618.5 million.
Our global rebate and discount liabilities are included in sales
rebates and discounts on our consolidated balance sheet. Our
global sales return liability is included in other current
liabilities and other noncurrent liabilities on our consolidated
balance sheet. Approximately 80 percent and 78 percent
of our global sales return, rebate, and discount liability
resulted from sales of our products in the U.S. as of
December 31, 2008 and 2007, respectively. The following
represents a roll-forward of our most significant
U.S. returns, rebate, and discount liability balances,
including Medicaid (in millions):
Revenue Recognition and Sales Return, Rebate, and Discount Accruals We recognize revenue from sales of products at the time title of goods passes to the buyer and the buyer assumes the risks and rewards of ownership. For more than 90 percent of our sales, this is at the time products are shipped to the customer, typically a wholesale distributor or a major retail chain. The remaining sales, which are outside the U.S., are recorded at the point of delivery. Provisions for returns, rebates, and discounts are established in the same period the related sales are recorded. We regularly review the supply levels of our significant products sold to major wholesalers in the U.S. and in major markets outside the U.S., primarily by reviewing periodic inventory reports supplied by our major wholesalers and available prescription volume information for our products, or alternative approaches. We attempt to maintain wholesaler inventory levels at an average of approximately one month or less on a consistent basis across our product portfolio. Causes of unusual wholesaler buying patterns include actual or anticipated product supply issues, weather patterns, anticipated changes in the transportation network, redundant holiday stocking, and changes in wholesaler business operations. In the U.S., the current structure of our arrangements eliminates the incentive for speculative wholesaler buying and provides us improved data on inventory levels at our wholesalers. When we believe wholesaler purchasing patterns have caused an unusual increase or decrease in the sales of a major product compared with underlying demand, we disclose this in our product sales discussion if we believe the amount is material to the product sales trend; however, we are not always able to accurately quantify the amount of stocking or destocking. Wholesaler stocking and destocking activity historically has not caused any material changes in the rate of actual product returns. We establish sales return accruals for anticipated product returns. We record the return amounts as a deduction to arrive at our net sales. Once the product is returned, it is destroyed. Consistent with SFAS 48, Revenue Recognition When Right of Return Exists, we estimate a reserve when the sales occur for future product returns related to those sales. This estimate is primarily based on historical return rates as well as specifically identified anticipated returns due to known business conditions and product expiry dates. Actual product returns have been approximately one percent of our net sales over the past three years and have not fluctuated significantly as a percent of sales. We establish sales rebate and discount accruals in the same period as the related sales. The rebate and discount amounts are recorded as a deduction to arrive at our net sales. Sales rebates and discounts that require the use of judgment in the establishment of the accrual include Medicaid, managed care, Medicare, chargebacks, long-term-care, hospital, patient assistance programs, and various other government programs. We base these accruals primarily upon our historical rebate and discount payments made to our customer segment groups and the provisions of current rebate and discount contracts. The largest of our sales rebate and discount amounts are rebates associated with sales covered by Medicaid. In determining the appropriate accrual amount, we consider our historical Medicaid rebate payments by product as a percentage of our historical sales as well as any significant changes in sales trends, an evaluation of the current Medicaid rebate laws and interpretations, the percentage of our products that are sold to Medicaid recipients, and our product pricing and current rebate and discount contracts. Although we accrue a liability for Medicaid rebates at the time we record the sale (when the product is shipped), the Medicaid rebate related
to that sale is typically paid up to six months later. Because of this time lag, in any particular period our rebate adjustments may incorporate revisions of accruals for several periods. Most of our rebates outside the U.S. are contractual or legislatively mandated and are estimated and recognized in the same period as the related sales. In some large European countries, government rebates are based on the anticipated pharmaceutical budget deficit in the country. A best estimate of these rebates, updated as governmental authorities revise budgeted deficits, is recognized in the same period as the related sale. If our estimates are not reflective of the actual pharmaceutical budget deficit, we adjust our rebate reserves. We believe that our accruals for sales returns, rebates, and discounts are reasonable and appropriate based on current facts and circumstances. Sales returns, federally mandated Medicaid rebate and state pharmaceutical assistance programs (Medicaid) and Medicare rebates reduced sales by $1.03 billion, $738.8 million, and $704.8 million in 2008, 2007, and 2006, respectively. A 5 percent change in the sales return, Medicaid, and Medicare rebate amounts we recognized in 2008 would lead to an approximate $52 million effect on our income before income taxes. As of December 31, 2008, our sales returns, Medicaid, and Medicare rebate liability was $618.5 million. Our global rebate and discount liabilities are included in sales rebates and discounts on our consolidated balance sheet. Our global sales return liability is included in other current liabilities and other noncurrent liabilities on our consolidated balance sheet. Approximately 80 percent and 78 percent of our global sales return, rebate, and discount liability resulted from sales of our products in the U.S. as of December 31, 2008 and 2007, respectively. The following represents a roll-forward of our most significant U.S. returns, rebate, and discount liability balances, including Medicaid (in millions):
| EXCERPTS ON THIS PAGE:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||